Delivering Advanced Therapeutics
Product Pipeline
Critical Pharmaceuticals is developing a pipeline of unique biological drug products utilizing its proprietary CriticalSorb and CriticalMix drug delivery technologies.
CP024 nasal growth hormone (hGH or somatropin) is in phase 1 clinical development for growth hormone deficiency in children and adults where our intranasal spray has shown comparable activity (IGF-1 induction) to an injection of marketed drug. CP024 uses Critical Pharmaceuticals CriticalSorb drug delivery technology.
CP046 nasal teriparatide (parathyroid hormone or PTH 1-34) for the treatment of osteoporosis is being developed in collaboration with the University of Nottingham and uses Critical Pharmaceuticals CriticalSorb technology.
CP016 is a long acting injection of human growth hormone (hGH or somatropin) in preclinical development for the treatment of growth hormone deficiency in children and adults that uses Critical Pharmaceuticals CriticalMix technology.
CP018 is a long acting injection of risperidone in formulation development for the treatment of schizophrenia and other psychiatric disorders that uses Critical Pharmaceuticals CriticalMix technology.
Critical Pharmaceuticals Product Pipeline
| Formulation Development | Preclinical Proof of Concept | Phase 1 Clinical |
| CP024: Nasal hGH | ||
| CP046: Nasal PTH | ||
| CP016: hGH Depot | ||
| CP018: Risperidone | ||
| Partnered Program | ||
Professor Lisbeth Illum
“We are very encouraged with the interim results from our Phase 1 program that show for the first time that nasal administration of hGH is able to induce IGF-1 to the same levels as a subcutaneous injection. Importantly, CP024 has also been shown to be well tolerated in repeat nasal toxicological studies and in our first human clinical trial. We look forward to starting a Phase 1b study shortly and continuing the development of CP024 to bring intranasal hGH to patients as an attractive alternative to daily injection”.
